BioDiem is an Australian biopharmaceutical company that is focused on developing and commercialising vaccines and infectious disease therapies.
Our business model is to generate income from partnerships including with other vaccine and infectious disease treatment companies through existing and new licences to its LAIV vaccine and other technologies. We have an established influenza vaccine licensing business. Our revenue comes from licence fees and royalties on sales.
Our lead asset, the LAIV (Live Attenuated Influenza Virus) vaccine technology, is used for production of seasonal and pandemic influenza vaccines and is given intranasally. This technology is licensed currently to two commercial partners, in India and China, and is licenced to the World Health Organisation as part of the Global Pandemic Influenza Action Plan to Increase Vaccine Supply. Nasovac-S™ is based on BioDiem’s technology and is already marketed in India and has WHO Prequalification certification. In 2017 BioDiem’s Chinese licencee, Changchun BCHT Biotechnology Co completed Phase III clinical trials in China.
BDM-I is BioDiem’s novel antimicrobial compound targeting the treatment of serious human infections. The compound is active against a range of disease-causing micro-organisms and is covered by worldwide patents. BioDiem’s subsidiary, Opal Biosciences Ltd, was established to develop the BDM-I technology to allow outside investment in the project and to help fast track BDM-I studies.
For more information, please visit: http://www.opalbiosciences.com/ (Follow us on twitter @opalbiosciences)
BioDiem welcomes inquiries from shareholders and potential partners. Contact email@example.com
Follow us on twitter: @biodiem